JPM: Biotech Values Dive While Industry Remains Optimistic
This article was originally published in Scrip
Executive Summary
Most of the time when biopharma CEOs and health care-focused investment bankers descend on San Francisco's Union Square in mid-January to assess the industry's status for the months ahead, biotech stocks rise as companies announce deals and data, but that's not what happened this year.